ENANTA PHARMACEUTICALS, INC Lease, Cost
ENANTA PHARMACEUTICALS, INC (ENTA) reported Lease, Cost of $15.62 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC lease, cost for the quarter ending 2020-09-30 was $2.11M.
- ENANTA PHARMACEUTICALS, INC lease, cost for the quarter ending 2020-06-30 was $1.42M.
- ENANTA PHARMACEUTICALS, INC lease, cost for the quarter ending 2020-03-31 was $1.44M.
- ENANTA PHARMACEUTICALS, INC lease, cost for the quarter ending 2019-12-31 was $1.14M.
- ENANTA PHARMACEUTICALS, INC lease, cost for fiscal 2025 was $15.62M, a 2.11% increase from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC lease, cost for fiscal 2024 was $15.29M, a 32.05% increase from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC lease, cost for fiscal 2023 was $11.58M, a 33.60% increase from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC lease, cost for fiscal 2022 was $8.67M, a 12.59% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-09-30 | $15.62M 10-K · filed 2025-11-19 | |||
| 2024-09-30 | $15.29M 10-K · filed 2025-11-19 | |||
| 2023-09-30 | $11.58M 10-K · filed 2025-11-19 | |||
| 2022-09-30 | $8.67M 10-K · filed 2024-11-27 | |||
| 2021-09-30 | $9.92M 10-K · filed 2023-11-22 | |||
| 2020-09-30 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24 | $3.53M derived: sum of 2 quarters · filed 2021-11-24 | $4.97M derived: sum of 3 quarters · filed 2021-11-24 | $6.11M 10-K · filed 2021-11-24 |
| 2020-06-30 | $1.42M 10-Q · filed 2020-08-10 | $2.86M derived: sum of 2 quarters · filed 2020-08-10 | $4.00M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $1.44M 10-Q · filed 2020-05-11 | $2.58M 10-Q · filed 2020-05-11 | ||
| 2019-12-31 | $1.14M 10-Q · filed 2020-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |